MARKET

DNLI

DNLI

Denali Therapeut
NASDAQ
18.77
-0.41
-2.14%
After Hours: 18.79 +0.02 +0.11% 17:27 02/13 EST
OPEN
19.24
PREV CLOSE
19.18
HIGH
20.12
LOW
18.61
VOLUME
1.34M
TURNOVER
--
52 WEEK HIGH
23.77
52 WEEK LOW
10.57
MARKET CAP
2.92B
P/E (TTM)
-6.4480
1D
5D
1M
3M
1Y
5Y
1D
Denali Therapeutics: Differentiated Hunter Syndrome Strategy and Non-Viral Platform Support Buy Rating and Long-Term Franchise Upside
TipRanks · 3d ago
FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment
Benzinga · 5d ago
Morgan Stanley Reaffirms Their Buy Rating on Denali Therapeutics (DNLI)
TipRanks · 5d ago
Assessing Denali Therapeutics (DNLI) Valuation After WORLDSymposium Clinical Updates And Regulatory Progress
Simply Wall St · 5d ago
Weekly Report: what happened at DNLI last week (0202-0206)?
Weekly Report · 6d ago
Denali Therapeutics (DNLI) Gets a Buy from Wedbush
TipRanks · 02/06 14:15
Denali Therapeutics: Strengthening LSD Clinical Profile and Attractive Risk‑Reward Support Buy Rating
TipRanks · 02/06 11:36
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), Akebia Therapeutics (AKBA) and Denali Therapeutics (DNLI)
TipRanks · 02/06 11:30
More
About DNLI
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.

Webull offers Denali Therapeutics Inc stock information, including NASDAQ: DNLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DNLI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DNLI stock methods without spending real money on the virtual paper trading platform.